Atlas Trials

Clostridioides Difficile Infection

43 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Clostridioides Difficile Infection

RecordFirmDate
Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection (NCT05304715)Hellenic Institute for the Study of Sepsis2022-04-13
Effect of Oral Microbiota on MDRO Decolonization (NCT07496502)Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran2022-03-31
Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection (NCT04885946)Christian Hvas2021-06-02
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) (NCT04305769)University of Virginia2021-06-01
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects (NCT04802837)Summit Therapeutics2021-05-19
Addressing Personalized Needs in Clostridioides Difficile Infection (NCT04725123)Hellenic Institute for the Study of Sepsis2021-01-26
Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection (NCT04781387)Crestone, Inc2021-01-05
The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infection (NCT04679324)Mayo Clinic2019-09-23
The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection (NCT04675723)Mayo Clinic2019-09-23
The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile Infection (NCT04668014)Mayo Clinic2019-09-01
Ursodeoxycholic Acid in C. Difficile Infection (NCT05526807)Nottingham University Hospitals NHS Trust2019-05-08
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection (NCT03788434)Vedanta Biosciences, Inc.2019-02-08
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (NCT03595553)Summit Therapeutics2019-01-28
ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection (NCT03183141)Seres Therapeutics, Inc.2017-10-23
Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections (NCT03895593)The Second Hospital of Nanjing Medical University2015-09-25
Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI) (NCT02437500)Seres Therapeutics, Inc.

Track Clostridioides Difficile Infection automatically

Every clearance here is in the API, with alerts when new ones post.